Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2154718 | 0.91 | L3MBTL1 (0.42) | TSHRLMNATYRALDH1A1SRD5A2 | |
| SCHEMBL13715604 | 0.85 | CYP2D6 (0.43) | TSHRLMNATYRALDH1A1HIF1A | |
| SCHEMBL14246524 | 0.80 | TSHR (0.44) | TSHRLMNATYRALDH1A1HDAC1 | |
| SCHEMBL8386750 | 0.80 | LMNA (0.48) | TSHRLMNATYRALDH1A1HDAC1 | |
| SCHEMBL424728 | 0.76 | TSHR (0.73) | TSHRLMNATYRALDH1A1HDAC1 | |
| SCHEMBL16241997 | 0.75 | TSHR (0.55) | TSHRLMNATYRALDH1A1HDAC1 | |
| SCHEMBL1305234 | 0.74 | GABRA1 (0.46) | TSHRALDH1A1NPC1MAPTRAB9A | |
| SCHEMBL6933048 | 0.74 | CES2 (0.46) | TSHRALDH1A1SRD5A2KIF11CYP1A2 | |
| SCHEMBL4320820 | 0.73 | CA1 (0.44) | TSHRLMNATYRALDH1A1CA1 | |
| SCHEMBL2154623 | 0.72 | HDAC8 (0.43) | ALDH1A1KIF11NPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117143150-A | Preparation method of chiral 2-hydroxyphosphinic oxide and derivative thereof | 广西大学 | 2023-12-01 | — | — | CN | claimed |
| CN-120004942-A | Method for synthesizing phosphorothioate compound by using manganese acetate dihydrate | 苏州大学 | 2025-05-16 | — | — | CN | disclosed |
| CN-117164627-B | Ketone phosphine oxide compound containing trifluoromethyl quaternary carbon center, preparation method and application thereof | 南京工业大学 | 2025-04-22 | — | — | CN | disclosed |
| CN-115403623-B | Method for preparing 2-pyrrolyl substituted phosphine oxide compound | 湖南理工学院 | 2024-10-29 | — | — | CN | disclosed |
| CN-118652272-A | Method for synthesizing thiophosphorus/phosphinic acid ester compound | 中国人民解放军军事科学院防化研究院 | 2024-09-17 | — | — | CN | disclosed |
| CN-114805430-B | Preparation method of selenophosphide and thiophosphoride | 烟台大学 | 2024-02-13 | — | — | CN | disclosed |
| CN-117164627-A | Ketone phosphine oxide compound containing trifluoromethyl quaternary carbon center, preparation method and application thereof | 南京工业大学 | 2023-12-05 | — | — | CN | disclosed |
| CN-117143150-A | Preparation method of chiral 2-hydroxyphosphinic oxide and derivative thereof | 广西大学 | 2023-12-01 | — | — | CN | disclosed |
| CN-116695147-A | Electrochemical synthesis method of phenylethynyl phosphine oxide derivative | 上海兆维科技发展有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-115572310-A | Preparation method of alpha, alpha-disubstituted-gamma-ketophosphine oxide | 西北民族大学 | 2023-01-06 | — | — | CN | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | SPERA PHARMA, INC. (JP) | 2007-07-12 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-7208633-B2 | Process for preparation of diphosphine compounds and intermediates for the process | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-24 | — | — | US | disclosed |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | SPERA PHARMA, INC. (JP) | 2005-02-03 | — | — | US | disclosed |
| EP-1452537-A1 | PROCESS FOR PREPARATION OF DIPHOSPHINE COMPOUNDS AND INTERMEDIATES FOR THE PROCESS | Takeda Chemical Industries, Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6730629-B2 | HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20030139285-A1 | Novel asymmetric phosphine ligand | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2003-07-24 | — | — | US | disclosed |
| EP-1318156-A1 | Novel asymmetric phosphine ligand | Takasago International Corporation (JP) | 2003-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161805-A1 | Phosphine-borane complex enantiomorph compounds produced in solvents and in the presence of nickel catalysts; useful for asymmetric synthesis of compounds useful as drug for prophylaxis or treatment of increased urinary frequency or urinary incontinence, Alzheimer's disease | BACE1, H1-10, PRMT1 | TSHR 1972/4885LMNA 2776/4885TYR 4124/4885 |
| US-20050027124-A1 | Process for preparation of diphosphine compounds and intermediates for the process | H1-10, ITPA, RER1 | TSHR 1089/4885LMNA 2061/4885TYR 1367/4885 |
| US-20030139285-A1 | Novel asymmetric phosphine ligand | PHOSPHO1, PAPSS1, PPM1F | TSHR 2674/4885LMNA 4820/4885TYR 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.